Home › Funds › EVENTIDE ASSET MANAGEMENT, LLC › KYMR
EVENTIDE ASSET MANAGEMENT, LLC position in KYMR
KYMERA THERAPEUTICS INC · Health Care
EVENTIDE ASSET MANAGEMENT, LLC reported holding 490,611 shares of KYMR (KYMERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$54.8M, representing 0.77% of its reported portfolio and ranking #39 among its reported holdings. EVENTIDE ASSET MANAGEMENT, LLC has disclosed KYMR holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How EVENTIDE ASSET MANAGEMENT, LLC's KYMR position evolved
EVENTIDE ASSET MANAGEMENT, LLC first disclosed a stake in KYMR in Q1 2024 at 19,774 shares (US$795K). The position peaked in Q2 2026 at 504,210 shares, worth US$57.8M. Across 11 filings, EVENTIDE ASSET MANAGEMENT, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 490,611 shares valued at US$54.8M — a reduction of -13,599 shares quarter over quarter.. Notable position changes include a 2237% increase in Q2 2024 (shares rose 59% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 19.77K | $794.91K | New |
| Q2 2024 | 462.10K | $13.79M | Add |
| Q3 2024 | 507.90K | $24.04M | Add |
| Q4 2024 | 455.73K | $18.33M | Reduce |
| Q1 2025 | 525.14K | $14.37M | Add |
| Q2 2025 | 562.99K | $24.57M | Add |
| Q3 2025 | 644.59K | $36.48M | Add |
| Q4 2025 | 626.43K | $48.74M | Reduce |
| Q1 2026 | 626.92K | $52.21M | Hold |
| Q2 2026 | 504.21K | $57.81M | Reduce |
| Q3 2026 | 490.61K | $54.84M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KYMR and 13F data
KYMR (KYMERA THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in KYMR — the largest reported positions include BAKER BROS. ADVISORS LP (US$992.7M), Avoro Capital Advisors LLC (US$857.1M), T. Rowe Price Investment Management, Inc. (US$717.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KYMR
- BAKER BROS. ADVISORS LP 8.66M sh · $992.73M · Q2 2026
- Avoro Capital Advisors LLC 7.47M sh · $857.13M · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.26M sh · $717.52M · Q2 2026
- BVF INC/IL 3.87M sh · $444.01M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 2.85M sh · $318.33M · Q3 2026
- Siren, L.L.C. 2.78M sh · $311.32M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 919.23K sh · $105.41M · Q2 2026
- Merck & Co., Inc. 772.16K sh · $86.32M · Q3 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 740.87K sh · $84.96M · Q2 2026
- Rock Springs Capital Management LP 453.16K sh · $51.96M · Q2 2026
- Boxer Capital Management, LLC 429.10K sh · $49.20M · Q2 2026
- BRAIDWELL LP 378.16K sh · $43.36M · Q2 2026
More on EVENTIDE ASSET MANAGEMENT, LLC
FAQ
How long has EVENTIDE ASSET MANAGEMENT, LLC held KYMR?
EVENTIDE ASSET MANAGEMENT, LLC has disclosed KYMR holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is EVENTIDE ASSET MANAGEMENT, LLC's current position in KYMR?
As of Q3 2026, EVENTIDE ASSET MANAGEMENT, LLC holds 490.61K shares of KYMR (KYMERA THERAPEUTICS INC), valued at $54.84M, representing 0.77% of its reported portfolio and ranking #39.
Has EVENTIDE ASSET MANAGEMENT, LLC been buying or selling KYMR?
In the latest 13F filing (Q3 2026), EVENTIDE ASSET MANAGEMENT, LLC reduced its position in KYMR. The position peaked in Q2 2026 at 504.21K shares.
Which other funds hold KYMR?
Other major institutional holders of KYMR include BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC, T. Rowe Price Investment Management, Inc., among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.